38 CFR Part 4 — 38 CFR § 4.118
Bullous disorders, including porphyria cutanea tarda — VA Diagnostic Code 7815
Skin
Diagnostic code
7815
38 CFR § 4.118 lists Diagnostic Code 7815 as “Bullous disorders (including pemphigus vulgaris, pemphigus foliaceous, bullous pemphigoid, dermatitis herpetiformis, epidermolysis bullosa acquisita, benign chronic familial pemphigus (Hailey-Hailey), and porphyria cutanea tarda).” The code says to evaluate under the General Rating Formula for the Skin. The note rates mucosal complications separately. Section 3.309(e) lists “Porphyria cutanea tarda.” It does not list the other disorders named in that parenthetical. Section 3.307(a)(6)(ii) requires porphyria cutanea tarda to become manifest to a degree of 10 percent or more within a year after the last date of herbicide exposure.
Reviewed 2026-10-05. Text checked against the eCFR versioner full-text XML for 2026-10-01 on 2026-10-05. Title 38 was up to date as of 2026-10-01 and last amended on 2026-08-27. The § 4.118 source note prints 67 FR 49596, July 31, 2002; 67 FR 58448, 58449, Sept. 16, 2002; 73 FR 54710, Oct. 23, 2008; 77 FR 2910, Jan. 20, 2012; 83 FR 32597, July 13, 2018; 83 FR 38663, Aug. 7, 2018.
The rating criteria at each level
7815 Bullous disorders (including pemphigus vulgaris, pemphigus foliaceous, bullous pemphigoid, dermatitis herpetiformis, epidermolysis bullosa acquisita, benign chronic familial pemphigus (Hailey-Hailey), and porphyria cutanea tarda)
Rating %: —
Criteria (verbatim). Evaluate under the General Rating Formula for the Skin
| Rating % | Criteria (verbatim) |
|---|---|
| — | Evaluate under the General Rating Formula for the Skin |
General Rating Formula For The Skin For DCs 7806, 7809, 7813-7816, 7820-7822, and 7824
Rating %: 60
Criteria (verbatim). At least one of the following
Rating %: —
Criteria (verbatim). Characteristic lesions involving more than 40 percent of the entire body or more than 40 percent of exposed areas affected; or
Rating %: 60
Criteria (verbatim). Constant or near-constant systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, psoralen with long-wave ultraviolet-A light (PUVA), or other immunosuppressive drugs required over the past 12-month period
Rating %: 30
Criteria (verbatim). At least one of the following
Rating %: —
Criteria (verbatim). Characteristic lesions involving 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected; or Systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of 6 weeks or more, but not constantly, over the past 12-month period
Rating %: 10
Criteria (verbatim). At least one of the following
Rating %: —
Criteria (verbatim). Characteristic lesions involving at least 5 percent, but less than 20 percent, of the entire body affected; or
Rating %: —
Criteria (verbatim). At least 5 percent, but less than 20 percent, of exposed areas affected; or
Rating %: —
Criteria (verbatim). Intermittent systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of less than 6 weeks over the past 12-month period
Rating %: 0
Criteria (verbatim). No more than topical therapy required over the past 12-month period and at least one of the following
Rating %: —
Criteria (verbatim). Characteristic lesions involving less than 5 percent of the entire body affected; or
Rating %: —
Criteria (verbatim). Characteristic lesions involving less than 5 percent of exposed areas affected
Rating %: —
Criteria (verbatim). Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, 7802, 7804, or 7805), depending upon the predominant disability. This rating instruction does not apply to DC 7824
| Rating % | Criteria (verbatim) |
|---|---|
| 60 | At least one of the following |
| — | Characteristic lesions involving more than 40 percent of the entire body or more than 40 percent of exposed areas affected; or |
| 60 | Constant or near-constant systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, psoralen with long-wave ultraviolet-A light (PUVA), or other immunosuppressive drugs required over the past 12-month period |
| 30 | At least one of the following |
| — | Characteristic lesions involving 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected; or Systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of 6 weeks or more, but not constantly, over the past 12-month period |
| 10 | At least one of the following |
| — | Characteristic lesions involving at least 5 percent, but less than 20 percent, of the entire body affected; or |
| — | At least 5 percent, but less than 20 percent, of exposed areas affected; or |
| — | Intermittent systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of less than 6 weeks over the past 12-month period |
| 0 | No more than topical therapy required over the past 12-month period and at least one of the following |
| — | Characteristic lesions involving less than 5 percent of the entire body affected; or |
| — | Characteristic lesions involving less than 5 percent of exposed areas affected |
| — | Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, 7802, 7804, or 7805), depending upon the predominant disability. This rating instruction does not apply to DC 7824 |
Note: Rate complications and residuals of mucosal involvement (ocular, oral, gastrointestinal, respiratory, or genitourinary) separately under the appropriate diagnostic code.
(a) For the purposes of this section, systemic therapy is treatment that is administered through any route (orally, injection, suppository, intranasally) other than the skin, and topical therapy is treatment that is administered through the skin.
(b) Two or more skin conditions may be combined in accordance with § 4.25 only if separate areas of skin are involved. If two or more skin conditions involve the same area of skin, then only the highest evaluation shall be used.
eCFR prints “At least one of the following” on its own row, with the percentage in the rating column, and prints the options on the following rows. A blank rating cell on this page marks an option row. It is not an extra level. On the 60 percent block, the rating column also shows 60 on the systemic-therapy row, which is how the eCFR table prints that block. 38 CFR § 4.7 assigns the higher rating when the disability picture more nearly approximates the criteria required for that rating. Otherwise, the lower rating will be assigned. 38 CFR § 4.6 requires each element affecting the evidence to be studied so that decisions will be equitable and just.
The formula header names DCs 7806, 7809, 7813-7816, 7820-7822, and 7824. DC 7815 is inside 7813-7816. The last formula line says the disfigurement-or-scars instruction does not apply to DC 7824. DC 7815 is not DC 7824. DC 7829 is “Chloracne.” It prints its own deep-acne and superficial-acne lines. It is not in the formula header, and its title does not include porphyria cutanea tarda.
The DC 7815 note names mucosal involvement of the ocular, oral, gastrointestinal, respiratory, or genitourinary systems. DC 7816 prints a different note, about psoriatic arthritis and other clinical manifestations. That note is not printed under DC 7815. 38 CFR § 4.14 says the evaluation of the same disability under various diagnoses is to be avoided, and that the evaluation of the same manifestation under different diagnoses is to be avoided.
Source: 38 CFR § 4.118, Diagnostic Code 7815 and the General Rating Formula for the Skin, eCFR full-text XML for 2026-10-01.
What the words mean in your records
Seven disorders in one title
The schedule title names pemphigus vulgaris, pemphigus foliaceous, bullous pemphigoid, dermatitis herpetiformis, epidermolysis bullosa acquisita, benign chronic familial pemphigus (Hailey-Hailey), and porphyria cutanea tarda. The same formula applies to that code. Section 3.309(e) names “Porphyria cutanea tarda.” The 2026-10-01 text does not name the other six disorders in that parenthetical.
Percent of skin, or systemic therapy, over 12 months
More than 40 percent of the entire body or of exposed areas, or constant or near-constant systemic therapy over the past 12-month period, is in the 60 percent block. Twenty to 40 percent, or systemic therapy for a total duration of 6 weeks or more, but not constantly, is in the 30 percent block. At least 5 percent but less than 20 percent, or intermittent systemic therapy for a total duration of less than 6 weeks, is in the 10 percent block. No more than topical therapy, with less than 5 percent of the entire body or of exposed areas, is the 0 percent block. 38 CFR § 4.118(a) says systemic therapy is treatment administered through any route (orally, injection, suppository, intranasally) other than the skin, and topical therapy is treatment administered through the skin. The schedule does not define “characteristic lesions” or “exposed areas” in a sentence under DC 7815.
Within a year after the last herbicide exposure
38 CFR § 3.307(a)(6)(ii) says the § 3.309(e) diseases shall have become manifest to a degree of 10 percent or more at any time after service, except that chloracne or other acneform disease consistent with chloracne, porphyria cutanea tarda, and early-onset peripheral neuropathy shall have become manifest to a degree of 10 percent or more within a year after the last date on which the veteran was exposed to an herbicide agent during active military, naval, or air service. 38 CFR § 3.307(a)(1) says any period of service is sufficient for a specified disease under the conditions listed in § 3.309(e).
Evidence that speaks to each level
60, 30, 10, or 0 under the skin formula
What the rater needs to see. At least one finding in that block: the percent of the entire body or of exposed areas affected by characteristic lesions, or the systemic or topical therapy the block describes over the past 12-month period.
Where that usually lives. The skin examination and the treatment record for those 12 months.
Mucosal complications
What the rater needs to see. The DC 7815 note: complications and residuals of mucosal involvement of the ocular, oral, gastrointestinal, respiratory, or genitourinary system, rated separately under the appropriate diagnostic code.
Where that usually lives. The examination of that system.
The one-year herbicide rule, when the question is porphyria cutanea tarda
What the rater needs to see. If the question is the § 3.309(e) presumption for porphyria cutanea tarda, the last date of herbicide exposure and whether the disease became manifest to a degree of 10 percent or more within a year after that date. The other disorders named in the DC 7815 title are not § 3.309(e) names.
Where that usually lives. Service records for the exposure date, and medical records for the manifestation date.
VA’s public DBQ list, checked October 5, 2026, names “Skin Diseases” and, separately, “Scars.” The files are Skin Diseases and Scars.
The exam form
DC 7815 says to evaluate under the General Rating Formula for the Skin and prints a note for mucosal complications. This page does not say either form replaces that text.
Related codes and how they interact
The same formula covers other skin codes. The presumption names one disorder in this title.
DC 7813 and DC 7806 also say to evaluate under the General Rating Formula for the Skin. 38 CFR § 4.118(b) says two or more skin conditions may be combined in accordance with § 4.25 only if separate areas of skin are involved. If they involve the same area, only the highest evaluation shall be used.
DC 7829 is the schedule title “Chloracne.” Section 3.307(a)(6)(ii) names chloracne and porphyria cutanea tarda in the same one-year exception. They are not the same diagnostic code.
Secondary conditions and presumptions
38 CFR § 3.309(e) lists “Porphyria cutanea tarda” among the diseases associated with exposure to certain herbicide agents, when § 3.307(a)(6) is met and the rebuttable presumption provisions of § 3.307 are also satisfied. The 2026-10-01 text of that paragraph does not assign DC 7815.
38 CFR § 3.307(a)(6)(ii) is the sentence quoted above. Porphyria cutanea tarda is one of the three diseases in the one-year exception. Chloracne is DC 7829. Early-onset peripheral neuropathy is a separate § 3.309(e) name. The schedule does not give that name one diagnostic code on this page.
The 2026-10-01 text of 38 CFR § 3.309(a) does not name porphyria cutanea tarda. Section 3.309(b) does not name it. Section 3.309(c) does not name it. Section 3.309(f) does not name it. 38 CFR § 3.317 does not name it. 38 CFR § 3.316 does not name it. 38 CFR § 3.320, § 3.320a, and § 3.320b do not name it.
A separate question, when a presumption does not decide it, is a medical question on the facts under 38 CFR § 3.310. Paragraph (a) covers disability proximately due to or the result of a service-connected disease or injury. Paragraph (b) covers increase in severity and requires a medical baseline.
Short answers
What is the VA rating for DC 7815?
Under 38 CFR § 4.118, bullous disorders, including porphyria cutanea tarda, are evaluated under the General Rating Formula for the Skin at 60, 30, 10, or 0 percent. Mucosal complications are rated separately under the note. Education only. VA decides on the evidence.
Does § 3.309(e) assign DC 7815?
No. It lists “Porphyria cutanea tarda” and does not print a diagnostic code. The schedule title at DC 7815 includes those words and six other disorders. DC 7829 is chloracne, not porphyria cutanea tarda.
FAQ
How does VA rate DC 7815?
The code says to evaluate under the General Rating Formula for the Skin. The blocks are 60, 30, 10, and 0 percent. Each block is at least one listed finding: a percent of the entire body or of exposed areas, or therapy of a stated kind and duration over the past 12-month period. The note rates mucosal complications separately. A further formula line says to rate as disfigurement of the head, face, or neck, or as scars, depending upon the predominant disability. Education only.
Is every disorder in the DC 7815 title an herbicide presumption?
Section 3.309(e) lists “Porphyria cutanea tarda.” It does not list pemphigus vulgaris, pemphigus foliaceous, bullous pemphigoid, dermatitis herpetiformis, epidermolysis bullosa acquisita, or benign chronic familial pemphigus (Hailey-Hailey). Those names are in the schedule title. They are not in that herbicide list.
What is the time limit for porphyria cutanea tarda?
Section 3.307(a)(6)(ii) says porphyria cutanea tarda shall have become manifest to a degree of 10 percent or more within a year after the last date of herbicide exposure. The same sentence gives chloracne and early-onset peripheral neuropathy that one-year rule. It says the other § 3.309(e) diseases shall have become manifest to a degree of 10 percent or more at any time after service.
Next steps
- Read the decision for DC 7815, the percent of body or exposed area, the therapy over the past 12 months, and any separate code used for mucosal involvement.
- The free worksheet is a place to write the code, the findings, and the records you already have. It does not file a claim or protect a filing date. An accredited representative is at find a VSO.
- Other skin codes are on the skin diagnostic-code index. The category page is skin conditions.
Education only. Not legal or medical advice. My Claim Packet is not a VA-accredited representative and does not file claims. VA decides every claim on its own evidence.
Other codes in this body system
Nearby catalog entries in Skin, ordered by diagnostic code number. All Skin codes
- DC 7804Scar(s), unstable or painful
- DC 7805Scars, other; and other effects of scars evaluated under diagnostic codes 7800, 7801, 7802, or 7804
- DC 7806Dermatitis or eczema
- DC 7807Leishmaniasis, American (New World)
- DC 7808Leishmaniasis, Old World
- DC 7809Discoid lupus erythematosus
- DC 7811Tuberculosis luposa (lupus vulgaris)
- DC 7813Dermatophytosis
- DC 7816Psoriasis
- DC 7817Erythroderma
- DC 7818Malignant skin neoplasms
- DC 7819Benign skin neoplasms
- DC 7820Infections of the skin
- DC 7821Cutaneous manifestations of collagen-vascular diseases not listed elsewhere
- DC 7822Papulosquamous disorders not listed elsewhere
- DC 7823Vitiligo
Also: DC code lookup (tools) lists the same index in a compact layout.
Source: 38 CFR Part 4, Diagnostic Code 7815 • va.gov
⚠️ Important Disclaimer
This page provides general educational information based on public VA regulations and VA.gov resources. It is not legal or medical advice, and My Claim Packet is not a VA-accredited representative. Any worksheets or draft documents produced by the tools must be reviewed for accuracy and are not filed with VA for you. Ratings and service connection are decided case-by-case from the individual record. Consult a VA-accredited VSO, claims agent, attorney, or qualified clinician for help with your situation, and verify current rules using the linked official source.

